2024 First study niraparib

First study niraparib

Author: urxj

August undefined, 2024

WebSep 28, 2024 · The study assessed the efficacy of niraparib as maintenance treatment, as measured by progression free survival. Patients with a response to first-line platinum … WebFeb 1, 2024 · Niraparib late-breaking data: · First results from the Phase 3 MAGNITUDE study of niraparib in combination with abiraterone acetate plus prednisone as a first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations (Abstract #12) …

Niraparib plus nivolumab or niraparib plus ipilimumab in …

WebSep 6, 2024 · The study had a single arm: All participants were prescribed niraparib 300 mg per day, which was given as oral capsules. In order to assess the effectiveness of … WebJan 1, 2024 · The JASPER clinical trial studied a new combination treatment for advanced or metastatic non-small cell lung cancer (NSCLC). Pembrolizumab, a drug approved for … scotiabank theatre online

JASPER: Phase 2 trial of first-line niraparib plus ... - PubMed

WebNiraparib, an inhibitor of poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP), has been associated with significantly increased progression-free survival WebThe study was conducted in accordance with the eth-ical standards of the Declaration of Helsinki, and the ... ZEJULAR (Niraparib) for First-Line Maintenance Treat-mentofOvarianCancerinChina[Internet].GlobeNewswire News Room. 2024 [cited 2024 May 17]. Available from: WebOct 8, 2024 · BARCELONA – Niraparib improves PFS when given after first-line chemotherapy for advanced ovarian cancer, according to “potentially practice-changing” results from a phase 3 study. scotiabank theatre ottawa location

European Commission approves Zejula (niraparib) as first-line

Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to

Web1 day ago · In updated findings of the ENGOT-OV16/NOVA trial, final overall survival data of niraparib maintenance therapy showed a benefit for patients with recurrent ovarian cancer; however, mature data showed no significant benefit. ... The phase 2 KGOG3046 is the first study to show survival outcomes with the dual checkpoint blockades, durvalumab and ... WebSep 3, 2024 · Niraparib is an oral, selective PARP-1/2 inhibitor approved for the treatment of advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. … prek themes for the yearWebApr 11, 2024 · The phase III PRIMA study randomized 733 patients with stage III/IV ovarian cancer who responded to first-line platinum-based chemotherapy in a 2:1 ratio to receive maintenance niraparib (n = 487) or placebo (n = 246). 1,2 Patients were randomized within 12 weeks of finishing the last cycle of chemotherapy. The study met the primary … pre k therapy

"WebFeb 17, 2024 · Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy Technology … " - First study niraparib

First study niraparib

Janssen Data at ASCO GU Demonstrate Longstanding Leadership …

WebNov 30, 2024 · A study of niraparib combined with MGD013 in patients with advanced or metastatic solid tumor who failed prior treatment. clinicaltrials.gov. Updated April 1, 2024. Accessed November 30, 2024 ...

Did you know?

WebFeb 16, 2024 · Chi et al. Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. ASCO GU 2024. WebSep 3, 2024 · The primary strength of this study is that it represents one of the first investigations of a PARP inhibitor with a PD-1 inhibitor for the first-line treatment of NSCLC. Niraparib in combination with pembrolizumab …

WebThe recommended niraparib dose for first-line maintenance treatment of advanced ovarian cancer is based on body weight or platelet count. For patients weighing less than 77 kg … WebAug 7, 2024 · The results of the study formed the evidence basis for approval of niraparib as the only oral, once-daily PARPi as monotherapy maintenance treatment for women with first-line platinum-responsive advanced ovarian cancer, regardless of biomarker status, in both the USA and EU, and more recently the United Kingdom (Fig. 4).

WebMar 22, 2024 · Dr Li noted that niraparib is approved as first-line maintenance in ovarian cancer based on results of the PRIMA study (ClinicalTrials.gov Identifier: NCT02655016 … WebOct 29, 2024 · European Commission approves Zejula (niraparib) as first-line monotherapy maintenance treatment in advanced ovarian cancer . For media and investors only. ...

WebApr 11, 2024 · Of the total 142 patients, 93 received niraparib as first-line maintenance therapy, 31 as maintenance therapy for platinum-sensitive recurrent ovarian cancer, and 18 as salvage treatment. ... The study was conducted in accordance with the ethical standards of the Declaration of Helsinki, and the ethics committee of the main study center Fudan ...

WebJan 1, 2024 · This study f … The JASPER clinical trial studied a new combination treatment for advanced or metastatic non-small cell lung cancer (NSCLC). ... ≥50% (cohort 1) or 1%-49% (cohort 2) received first-line niraparib (200 mg once daily) plus pembrolizumab (200 mg every 3 weeks). The primary end point was investigator-assessed objective response ... prek toal tours and travelWebMay 26, 2024 · Niraparib (ZEJULA) is the first selective poly (ADP-ribose) polymerase inhibitor (PARPi) approved in the US and Europe for maintenance treatment in pts with recurrent OC regardless of BRCA mut status. Preclinical data suggest synergy with … prek toy foodWebApr 29, 2024 · On April 29, 2024, niraparib was approved for maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal … scotiabank theatre ottawa showtimesWebJul 2, 2024 · Study Description Go to Brief Summary: This study will evaluate the efficacy and safety of niraparib and novel treatment combinations of niraparib as described … scotiabank theatre saskatoon ticketsWebBackground: This study evaluated maintenance treatment with niraparib, a potent inhibitor of poly(ADP-ribose) polymerase 1/2, in patients with platinum-sensitive recurrent ovarian cancer. Patients and methods: In this phase III, double-blind, placebo-controlled study conducted at 30 centers in China, adults with platinum-sensitive recurrent ovarian cancer … pre k theme thanksgiving easy snacksWebApr 12, 2024 · The investigational PARP inhibitor senaparib (JS109/IMP4297) was found to prolong progression-free survival (PFS) in patients with advanced ovarian cancer, meeting the primary end point of the phase 3 FLAMES study (NCT04169997). 1. Senaparib was designed to selectively bind to PARP 1/2 and prevent PARP-mediated repair of single … scotiabank theatre nsWebMar 1, 2024 · The NDA is supported by data from the MAGNITUDE study (NCT03748641), a Phase 3, randomized, double-blind, placebo-controlled, multicenter study evaluating the safety and efficacy of niraparib plus AAP as a first-line treatment in patients with mCRPC, with or without alterations in HRR associated genes. 1 Patients with HRR gene … scotiabank theatre park lane